U2

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Thursday, September 15, 2022
Adult, Securities Exchange Act of 1934, Chronic lymphocytic leukemia, Multiple sclerosis, Complaint, Oncology Drug Advisory Committee, Risk, Biologics license application, FDA, Food, Company, Acquisition, Pomerantz, News, Review, Lists of action films, Prescription Drug User Fee Act, NDA, Therapy, Person, Survival, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Lymphoid leukemia, TG, Lists of schools in England, ODAC, Shanda, SEC Rule 10b-5, CLL, Degenerative disease, New Drug Application, Court, NASDAQ, Lymphocytosis, District court, Ext, Overalls, GLOBE, BLA, SLL, Death, Follicular lymphoma, Medical device, Pharmaceutical industry, High-performance plastics, Ublituximab, Umbralisib, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TG THERAPEUTICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, September 15, 2022
Class Action Lawsuit, Professional Services, Legal, Adult, Chronic lymphocytic leukemia, Multiple sclerosis, Oncology Drug Advisory Committee, Risk, Biologics license application, FDA, Food, Company, Acquisition, News, Review, Prescription Drug User Fee Act, NDA, P.C, Therapy, Person, Survival, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of schools in England, Lymphoid leukemia, TG, ODAC, Shanda, CLL, Degenerative disease, Jeanne Eagels, New Drug Application, Court, NASDAQ, Telephone, District court, BLA, Overalls, SLL, Death, Follicular lymphoma, Pharmaceutical industry, High-performance plastics, Ublituximab, Umbralisib, U2

Investors have until September 16, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 16, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • On this news, TG Therapeutics stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
  • On this news, TG Therapeutics stock price fell $1.93 per share, or 21.81%, to close at $6.92 per share on April 18, 2022.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, September 13, 2022
Adult, Securities Exchange Act of 1934, Chronic lymphocytic leukemia, Multiple sclerosis, Oncology Drug Advisory Committee, Lists of action films, Advertising, Risk, Biologics license application, FDA, Food, NEW, Company, News, Review, Prescription Drug User Fee Act, NDA, Therapy, Survival, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Investment, Lists of schools in England, TG, ODAC, Shanda, CLL, New Drug Application, NASDAQ, Court, District court, GLOBE, Overalls, BLA, Labour government, SLL, The Legal 500, Death, Follicular lymphoma, Tobacco, Pharmaceutical industry, High-performance plastics, Medical device, Ublituximab, Umbralisib, U2

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TG Therapeutics, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 16, 2022 Deadline; Portnoy Law Firm

Retrieved on: 
Wednesday, September 7, 2022
NDA, TG, Survival, Therapy, NASDAQ, Lists of schools in England, Overalls, Complaint, GLOBE, Company, FDA, U2, Review, Pharmaceutical industry, Umbralisib, Ublituximab

LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors that a class action filed on behalf of investors. TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) investors that a class action filed on behalf of investors.
  • TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, September 6, 2022
Patient, BLA, NDA, Securities Exchange Act of 1934, TG, Survival, District court, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, New Drug Application, Overalls, Food, Advertising, Court, CLL, Investment, NEW, GLOBE, Company, FDA, Labour government, News, The Legal 500, ODAC, Adult, Biologics license application, Lists of action films, SLL, Risk, Shanda, Prescription Drug User Fee Act, Review, Tobacco, Pharmaceutical industry, High-performance plastics, Medical device, Umbralisib, Ublituximab, U2

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Tuesday, September 6, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Lymphocytosis, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TGTX, YQ & ENOB Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate

Retrieved on: 
Thursday, September 1, 2022
Complaint, YQ, NDA, Prospectus, Survival, G-Technology, Register, Education, NASDAQ, Lists of schools in England, Overalls, IPO, Defendant, Court, Academy, SRI, GLOBE, Registration statement, Company, FDA, LLC, Fraud, U2, Pharmaceutical industry, Public relations, Umbralisib, Ublituximab

You can review a copy of the Complaints by visiting the links belowor you may contact Peretz Bronstein, Esq.

Key Points: 
  • You can review a copy of the Complaints by visiting the links belowor you may contact Peretz Bronstein, Esq.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at212-697-6484.
  • If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.

TG Therapeutics, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 16, 2022 Deadline; Portnoy Law Firm

Retrieved on: 
Wednesday, August 31, 2022
NDA, TG, Survival, Therapy, NASDAQ, Lists of schools in England, Overalls, Complaint, GLOBE, Company, FDA, U2, Review, Pharmaceutical industry, Umbralisib, Ublituximab

LOS ANGELES, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors that a class action filed on behalf of investors. TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) investors that a class action filed on behalf of investors.
  • TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Tuesday, August 30, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Lymphocytosis, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, August 30, 2022
Patient, BLA, NDA, Securities Exchange Act of 1934, TG, Survival, District court, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, New Drug Application, Overalls, Food, Advertising, Court, CLL, Investment, NEW, GLOBE, Company, FDA, Labour government, News, The Legal 500, ODAC, Adult, Biologics license application, Lists of action films, SLL, Risk, Shanda, Prescription Drug User Fee Act, Review, Tobacco, Pharmaceutical industry, High-performance plastics, Medical device, Umbralisib, Ublituximab, U2

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.